Shield Therapeutics plc announced that Greg Madison has been appointed as Chief Executive Officer with effect from 1 June 2021.  Greg has an excellent commercialisation track record and, in particular, he has deep knowledge and previous experience in the US iron deficiency marketplace. Greg is a seasoned executive who brings strong operating experience and a track record of success leading small to medium size organisations.  Prior to joining Shield, he was Chief Executive Officer at Melt Pharmaceuticals. Prior to Melt Pharmaceuticals, he was Chief Executive Officer of Keryx Biopharmaceuticals from 2015 to 2018, where he led the transformation of the organisation from development stage to commercial stage focused on Auryxia. In 2013 and 2014, he was Chief Commercial Officer at AMAG Pharmaceuticals where he was closely involved with Feraheme. From 2000-2012, Greg was at Genzyme Corporation, ultimately serving as Vice President and General Manager of its Nephrology Division. Greg began his career as a sales representative for Janssen Pharmaceuticals, a division of Johnson and Johnson. Tim Watts, Shield's current CEO, will step down as CEO on 1 June 2021 but will remain with the Group as an executive Director until 30 September 2021 to ensure an effective transition at which point he will also step down from the Board.